31

CLAIMS

1.   Use of an eIF4E binding agent in therapy.

2.   Use according to claim 1 for the induction of
programmed cell death.

3.   Use according to either of claims 1 or 2 wherein
the agent is a peptide or peptidemimetic.

4.   Use according to claim 3 wherein said peptide
comprises the sequence:

YxxxxLØ

wherein x is a variable amino acid and Ø is Leu, Met or
Phe;

or a fragment or derivative thereof.

5.   Use according to claim 4 wherein said peptide
comprises the sequence:

(K/R)xxYxxx(F/Q)L(L/M).

6.   Use according to claim 5 wherein said peptide
comprises the sequence:

KKRYDREFLLGF,

RVRYSDQLLDL, or

RIIYDRKL(L/M).

7.   Use according to any of claims 3 - 6 wherein said
peptide is 7 - 25 amino acids in length.

8.   Use of a peptide comprising sequence:

YxxxxLØ wherein x is a variable amino acid and Ø is Leu,

Met or Phe;

or fragment or derivate thereof in the manufacture of a

5   medicament for therapy, more particularly for inducing cell

death.

9.   Use according to claim 8 wherein the medicament

is used to induce cell death in tumour cells.

10

10.   Use of a polynucleotide fragment encoding a

peptide comprising sequence:

YxxxxLØ wherein x is a variable amino acid and Ø is Leu,

Met or Phe.

15

20

25